secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2023-04-14T23:59:59+00:00
Accession:  0001213900-23-029879
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax receives Nasdaq delisting notice for bid price non-compliance
--------------------------------------------------------------------

- Nasdaq notified Virpax on April 10, 2023 of non-compliance with Listing Rule 5550(a)(2) for bid price below $1.00.
- Company has 180 calendar days, until October 9, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not cured, Virpax may qualify for an additional 180-day period, subject to meeting other listing requirements and potential reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023029879/0001213900-23-029879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023029879/ea176786-8k_virpaxpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-029879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer